US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer

MLA

“US FDA Accepts for Priority Review GSK’s Application for an Expanded Indication of Jemperli (Dostarlimab) plus Chemotherapy to Include All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer.” European Union News, 24 Apr. 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.791694112&authtype=sso&custid=ns315887.

APA

US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer. (2024, April 24). European Union News.

Chicago

European Union News. 2024. “US FDA Accepts for Priority Review GSK’s Application for an Expanded Indication of Jemperli (Dostarlimab) plus Chemotherapy to Include All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer,” April 24. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.791694112&authtype=sso&custid=ns315887.